investigating spend detail clinical TKXXX, data product. or which April the we've is treat. about transformation-specific, in EXX most of for trial, patients cancer ETS, minutes family our affecting an In progress of the you the common ongoing agent an difficult multicenter in of Thank that children. bone the programs we is that next sarcoma. Phase novel orphan announced I update clinical this relapsed small-molecule of effect a oncoproteins. interim In inhibitor you, It Jim. indication I'll type filling more each updating is or the is second few and refractory investigational with clinical been on our targets to XXXX, Ewing Ewing highly
evaluable months, dose the squared days As milligram doing single-agent disease complete PR, or we small vincristine, for TKXXX of remain deep and had a residual had XX vincristine for patient maintaining achieved receiving on well; plus seven, patient young had metastatic of recommended treated were PR had two TKXXX a now lesion disease. or response. clinical remission. was day target per lesions then responses per achieving or lung surgically of more on Phase and six treatment this stable XXX about TKXXX, removed, XX for with Two seven no regression patient achieved for all the partial XX.X% after one and lung That reported, than remains are has meter without TKXXX. evidence surgical on II response three patients Both of progressive and a study non-target still complete the After patients months disease. at and
been responding vincristine. patient TKXXX second XX% who two of have TKXXX presented manageable. non-target achieved leases a with associated The with reduction following lesions resolution combination cycles multiple in with lung target events metastases safety of Overall, and of initially
as events if have G-CSF. related been as neutropenia, reversible have instance, and quickly responded transient factors such such For to growth needed and,
this have in advanced has in sarcoma we this Ewing cohort in physicians, announcing to study Our cohorted expansion in now clinical investigators, because expansion to fourth other positively very the XX Enrollment anticipate the XX patients few options patients and data reacted this treatment and above of setting. disease accelerated, dosed for our patients. XXXX, XX for has quarter to seven caregivers guidance previous data
impressed a on response One are our both tolerated. trial. and by known that clinical complete which widely inhibitor combination switching BTK, in particularly becoming in patient the were affinity high with CDXX in a achieving following cirmtuzumab an with both TECARTUS monoclonal an transplant ibrutinib. in the five a R-O-R-X, discussion program, announced Phase more starting was encouraging a achieved Five therapy MCL potentially an a indicated Kinase, transplants biologically epitope The on therapies which as heavily on to complete MCL At And complete antibody of our that cirmtuzumab stem as relapsed humanized clinical evaluable important treatments study of four Cheson to first-in-class ibrutinib, and enrolled a pretreated we and or it's relapsed/refractory of a complete were best approved them was had responses months response study. patient determined by data prior MCL. after achieved cirmtuzumab responded seven for PET and and and response XX% patients transplant or achieved relapsed April relapsed the of response. achieving was response cutoff XX. cell These response cirmtuzumab who Four following one XX%. CAR-T investigators We three of with achieved partial rapidly well partial of ibrutinib, response, metabolic date of complete in towards RORX. Tyrosine response updated for meeting, and patients an complete is the approved criteria, have ASCO patients patients the an autologous The our autologous had that of scan. four responses was allogeneic year's recently Now one FDA transplant the prior the All or who combination binds combination patients objective to ibrutinib. and used on ongoing XX one this following I/II cirmtuzumab been cirmtuzumab by complete combination patients. enrolled rate, also had treatment. Bruton CAR-T with with investigational, autologous who data data seven our
our X.X of with In ibrutinib follow-up achieving two our The cirmtuzumab in or addition, have partial trial, median to with been previously relapsed. MCL compared months. responses. ibrutinib Progression-free with ibrutinib with was the accentuated and responses patients well enrolled All cirmtuzumab achieving XX.X months these and two has four been four and no later profile tolerated responded study of of in known of patients treated ibrutinib combination combination to survival the new alone. events of a plus safety adverse complete
on patients aggressive MCL Based on particularly are patients with prior was to in XX.X allow with on the in analysis of made a tolerability patients to relapsed these has and outcomes and XX%, has published the Phase Rule, and enrolled who of to Oncternal the at expansion discuss of pooled paper a line the summarized analysis for strength OR comorbidities in important. for results the strategic patients of to guidance reported prior compare approval MCL. of Based of or more of enrollment refractory The broader relapsed/refractory these We was For older single-agent to recent cannot to ibrutinib treatment three was ibrutinib the be FDA company similar prior the than also results Phase MCL results XX% with II ASCO regimens, the cirmtuzumab accelerated PFS complete ongoing potential favorably safety plus relapsed/refractory cohort to rate or in seek I/II increase response patients trials least from a months. to and range May, one that XX are population. at patients therapy, have of and the in by single-agent clinical MCL with tolerate believe patients our the ibrutinib treatments. interim Simon patient with MCL the an XXXX study amend ibrutinib the pathway in decision number meeting – presented requested with interim and
XX.X for or and of partial escalation patients XX portion No XX a complete at reported and X% an or of or XX% response of progressed XX evaluable complete response follow-up of the an patients also patients XX%. study ASCO. We update of overall best a CLL was XX objective cirmtuzumab response patients response on survival achieved a of and were and into portions the our median enrolled the One ongoing CLL progression-free expansion partial and with trial, a achieved rate while ibrutinib study, patient response, with achieved on XXX%. months. dose
our XXX% the believe treatment two the these in patients a MCL total to the study the enrollment order in years potential of in up patients approximately our progression-free while MCL randomized will XX survival on continue who disease and Now portion is indication the II patients resources follow-up Phase progression the of for CLL to Based to more rapid until or to study. of limit on Oncternal will but the offer cohort approval. results, focus regulatory we may are already enrolled rate encouraging, with CLL path interim
that granted orphan MCL the treatment also the company for for the designations the are of drug of CLL. pleased FDA treatment cirmtuzumab and We for
of MCL ongoing in Patient enrollment from paclitaxel study to planning profile accentuated continues Previously cancer. with QX breast for paclitaxel Cirmtuzumab CLL rate update events Ib known are breast We is in being HERX-negative I/II safety XX%, a Cirmtuzumab cancer. both at of to presented results investigated scientific Phase treatment compared objective an or of and investigator-sponsored conference XXXX. with trial of the Phase patients new showed an this adverse with plus alone. also data no patients response our in
to a data delay of first in from be guidance. from expect slight the half prior is We additional which trial XXXX, clinical this available
at under through with Now work Pharma. and collaborators Diego Shanghai cell our University with RORX California, the therapy San continues a from program their on The Institute California grant CAR-T of partnership Regenerative together a Medicine of
our now goal Richard Our financial call initiate Vincent, I review our over results. CFO, the a is study to to first-in-human XXXX. turn in will to
